https://www.selleckchem.com/products/XL184.html
No patient developed liver failure, hepatocellular carcinoma or death. Cumulative rates of HBsAg loss were 2%, 4%, 7%, 10% and 20% at 3, 6, 12, 24 and 36months. HBsAg levels100IU/mL at the end of NA treatment could predict HBsAg loss (P=.001). Our study supports that NA therapy can be safely stopped in non-cirrhotic patients with HBeAg-negative CHB. Over a median follow-up of more than 5years, half of the patients remained without retreatment with a substantial proportion of them achieving functional cure. Our study supports that NA t